Glenmark/Lilly suspend trials with TRPV1 antagonist GRC 6211 in OA

Glenmark and Lilly have announced they have suspended further clinical development for TRPV1 antagonist GRC 6211 in Osteoarthritis pain.

NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN)

NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).

Evotec/Pfizer initiate Phase I trial of VR1 antagonist

Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist in collaboration with Pfizer

Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery

Anesiva have begun a Phase II clinical trial of Adlea, the company’s long-acting capsaicin product in for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

NeurogesX Initiate Phase I of NGX-1998 Capsaicin Liquid Formulation

NeurogesX has initiated a Phase 1 clinical trial of NGX-1998, a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

NeurogesX publish Phase III data on NGX-4010 in HIV neuropathy

NeurogesX have published Phase 3 data of its lead capsaicin product NGX-4010 in Neurology. The trial, in patients with HIV-associated distal sensory polyneuropathy (HIV-DSP) showed the drug to statistically reduce pain over a 12-week period.

Phase II trials of Adlea in post orthopedic surgery pain to take place in South Korea

Anesiva to begin Phase II trial of Capsaicin drug Adlea for use in the treatment of post orthopedic surgery pain.

NeurogesX submit IND for liquid formulation of Capsaicin, NGX-1998

NeurogesX have submitted an IND for the liquid formulation of Capsaicin, NGX-1998 for the treatment of pain